 |
| The race is on to find a treatment for Nonalcoholic Steatohepatitis (NASH), a silent liver epidemic that's asymptomatic and hard to diagnose. A next-generation approach to NASH clinical trials uses anonymized EHR and claims data, non-invasive diagnostics, and innovative site models. This can help you speed recruitment, optimize sites, shorten timelines and cut development costs.
|
|
| Attend this live webinar and learn how QuintilesIMS can help you achieve your goals in developing your NASH treatment.
|
|
| Gain a better understanding of NASH, and its complexity that makes this disease hard to diagnose. Execute your NASH trials with confidence, with a next-generation approach that provides:
|
 |
• |
|
Use of curated data to optimize your protocol and target sites |
|
|
• |
|
Novel technology to screen and stratify patients |
|
|
• |
|
An innovative site support model to better identify patients and accelerate recruitment |
|
|
|
|
|
|
|
| Presenters: |
|
Mark H. Delegge, MD
Senior Medical Director, QuintilesIMS |
|
Gavin Nichols
VP CRO/Life Science, Perspectum Diagnostics |
|
| Moderator: |
|
Lisa Henderson
Editorial Director, Applied Clinical Trials |
|
|
|
|
|
For technical questions about this webinar,
please contact Kristen Moore at kristen.moore@ubm.com |
|
|
|
| |
|
Contact us at
www.quintilesims.com
|
|
|
|
